nov 30, 2017 - FDA approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine- containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days.
Added to timeline:
Date:
nov 30, 2017
Now
~ 7 years and 10 months ago